Very stealthy Boulder-based Hiberna Corporation has landed rather subtly on the radar, appearing in a Forbes article last week (read the article (here)). The piece is focused upon a variety of companies and technologies who are pursuing the potential clinical application of hibernation in order to slow metabolism thereby extending survival limits in traumas that [...]

• 320http://clsdf.com/2008/02/hiberna-in-the-spotlight/Hiberna%3A+In+the+Spotlight2008-02-19+14%3A11%3A00admin

An agreement was reached with Longmont-based Chemizon and the Korean Research Institute of Bioscience and Biotechnology (KRIBB) to spin out a new biotech company designed to commercialize KRIBB’s intellectual property assets with an emphasis on technologies targeting the discovery of drugs that address unmet medical needs. The deal is led by Chemizon-Oakwood Bioventures private equity [...]

• 319http://clsdf.com/2008/02/chemizon-oakwood-bioventures-to-fund-newco/Chemizon-Oakwood+Bioventures+to+Fund+NewCo2008-02-15+15%3A36%3A00admin

News continues to pour out of Pharmion (NASDAQ: PHRM) of late and believe it or not today’s tidbit is not related to the Celgene (NASDAQ: CELG) acquisition, rather it is focused on the MGCD0103 product for the treatment of acute Myelogenous Leukemia with development and commercialization partner MethylGene (TSX: MYG). This week proved very encouraging [...]

• 318http://clsdf.com/2008/02/pharmion-market-exclusisivity/Pharmion%3A+Market+Exclusisivity2008-02-15+14%3A49%3A00admin

Tapestry Pharmaceuticals (NASDAQ: TPPH) is plummeting today down some 80% at the market open, a recent 8K filing with the SEC details the unfortunate preparation for bankruptcy filing due to an inability to finance continuing operations. A sad day and a black eye for the Colorado life science ecosystem indeed. Following are some of the [...]

• 317http://clsdf.com/2008/02/tapestry-pharma-comes-undone/Tapestry+Pharma+Comes+Undone2008-02-13+16%3A08%3A00admin

Did you know that the Canadian yew plant is recognized as the world’s largest natural reservoir for taxanes? It so happens that Bioxel Pharma (TSX: BIP) has harvesting rights on public and private lands covering an area of over 250,000 square kilometers with a high density of Canada yew. What does the Canadian yew have [...]

• 316http://clsdf.com/2008/02/bioxel-lafayette-yews-taxane/Bioxel+%2B+Lafayette+%3D+Yews+%2B+Taxane2008-02-12+19%3A08%3A00admin

Thank you for the emails re: last weeks post on Juvaris BioTherapeutics. This week I am continuing the theme of highlighting more of the private companies who though not headquartered in Colorado have a meaningful presence. One such company is Quark Pharmaceuticals who though headquartered in Freemont, CA maintains their development unit Boulder. Quark Pharmaceuticals [...]

• 315http://clsdf.com/2008/02/quark-boulder-sirna-clinical-candidates/Quark+%2B+Boulder+%3D+siRNA+Clinical+Candidates2008-02-11+15%3A38%3A00admin

Those of you who know me recognize I am a bit of a web 2.0 junkie and can often find me at the Boulder/Denver New Tech Meet-up. This interest stems from a number of close friends who are ‘in the biz’. There is not a new site going live that I’ll turn down a beta [...]

• 314http://clsdf.com/2008/02/plaxo-vs-linkedin-now-what/Plaxo+vs.+LinkedIn%3A+Now+What%3F2008-02-11+15%3A19%3A00admin

Just when you think the $2.9B Celgene (NASDAQ: CELG) acquisition of Pharmion (NASDAQ: PHRM) is all but a done deal enter one Steven A. Cohen of S|A|C Capital Advisors, a private asset management firm who with its sub CR Intrinsic Investments, hold in aggregate approximately 3 million shares of Pharmion and thus near 10% of [...]

• 313http://clsdf.com/2008/02/prhm-deal-not-good-enough-for-some/PRHM+Deal+Not+Good+Enough%2C+For+Some...2008-02-09+02%3A58%3A00admin

For those of you who do not know…Steven Dow, DVM, Ph.D., is the Founder and Chief Scientific Advisor of Juvaris Biotherapeutics. Dr. Dow currently serves as Associate Professor in the Departments of Clinical Sciences and Pathology in the College of Veterinary Medicine at Colorado State University and prior to that was an instructor and research [...]

• 312http://clsdf.com/2008/02/juvaris-biotherapeutics-colorado-roots/Juvaris+BioTherapeutics%3A+Colorado+Roots2008-02-08+02%3A54%3A00admin

Don’t miss this very special MIT Entrepreneurship Center full day seminar (sponsored exclusively by our friends at Faegre & Benson) on Thursday 14 February 9:00am – 7:30pm. This ‘one’ day high quality seminar and workshop is for CEOs and executives from young, fast-growing high tech companies featuring case studies and lectures, interactive discussions, student presentations, [...]

• 311http://clsdf.com/2008/02/mit-entrepreneurship-center-workshop/MIT+Entrepreneurship+Center+Workshop2008-02-06+14%3A48%3A00admin

Array Biopharma (NASDAQ: ARRY) is an incredibly well positioned tour de force biopharmaceutical company with a strong balance sheet, a vast portfolio of six wholly owned compounds, and a variety of pharma partnered development efforts with AstraZeneca (NYSE: AZN), Celgene (NASDAQ: CELG), InterMune (NASDAQ: ITMN) and Roche (Swiss: RO.SW). President and CEO Robert Conway and [...]

• 310View 1 Comment...http://clsdf.com/2008/02/array-q%e2%80%99ly-report-well-positioned/Array+Q%E2%80%99ly+Report%3A+Well+Positioned%212008-02-06+04%3A44%3A00admin

N30 Pharma is developing s-nitrosothiol therapies for critical unmet needs in respiratory diseases such as cystic fibrosis, asthma, and chronic obstructive pulmonary disease. A Phase I study of their lead molecule N30-201 used in healthy volunteers has been successfully completed. Safety and adverse events were characterized in addition to collecting pharmacokinetic and pharmacodynamic data of [...]

• 309http://clsdf.com/2008/02/n30-pharma-completes-phase-i-study/N30+Pharma+Completes+Phase+I+Study2008-02-04+14%3A59%3A00admin

Taligen Therapeutics announced the close of a $65M Series B financing led by Alta Partners and Clarus Ventures and with ongoing participation from existing partners Sanderling Ventures, Tango and High Country Venture. All I can say is ‘WOW’! I would be willing to bet a dollar that there is not a larger Series B financing [...]

• 308http://clsdf.com/2008/02/taligen-therapeutics-65m-series-b/Taligen+Therapeutics%3A+%2465M+Series+B2008-02-01+16%3A06%3A00admin